These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 375808)

  • 21. Thrombocytopenia secondary to high valproate levels in children with epilepsy.
    Delgado MR; Riela AR; Mills J; Browne R; Roach ES
    J Child Neurol; 1994 Jul; 9(3):311-4. PubMed ID: 7930412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transient thrombocytopenia in a child on sodium valproate.
    Cole AP
    Dev Med Child Neurol; 1978 Aug; 20(4):487-90. PubMed ID: 357235
    [No Abstract]   [Full Text] [Related]  

  • 23. Valproate-associated coagulopathies are frequent and variable in children.
    Attilakos A; Katsarou E; Voudris K; Garoufi A
    Epilepsia; 2007 Jan; 48(1):205-6. PubMed ID: 17241231
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical irrelevance of the hematologic side effects of sodium valproate (Depakine)].
    Loisseau P; Martínez-Lage JM
    Rev Med Univ Navarra; 1981 Sep; 25(3):14-6. PubMed ID: 6803320
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombocytopenia in patients treated with heparin, combination antiplatelet therapy, and intra-aortic balloon pump counterpulsation.
    Bream-Rouwenhorst HR; Hobbs RA; Horwitz PA
    J Interv Cardiol; 2008 Aug; 21(4):350-6. PubMed ID: 18537872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
    Waberzinek G; Marková J; Mastík J
    Neuro Endocrinol Lett; 2007 Feb; 28(1):59-64. PubMed ID: 17277725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of intravenous valproate.
    Devinsky O; Leppik I; Willmore LJ; Pellock JM; Dean C; Gates J; Ramsay RE
    Ann Neurol; 1995 Oct; 38(4):670-4. PubMed ID: 7574466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium valproate and platelet-count.
    Raworth RE; Birchall G
    Lancet; 1978 Mar; 1(8065):670-1. PubMed ID: 76214
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy of sodium valproate in partial epilepsy. Crossed study of valproate and carbamazepine].
    Loiseau P; Cohadon S; Jogeix M; Legroux M; Dartigues JF
    Rev Neurol (Paris); 1984; 140(6-7):434-7. PubMed ID: 6431586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Encephalopathy associated with hyperammonemia in an alcoholic patient treated with sodium valproate].
    Mattei A; Bernard G; Plauchu G; Paliard P
    Gastroenterol Clin Biol; 1993; 17(6-7):516-7. PubMed ID: 8243949
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.
    Jacobsen FM
    J Clin Psychiatry; 1993 Jun; 54(6):229-34. PubMed ID: 8331092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data.
    Buoli M; Serati M; Botturi A; Altamura AC
    Drugs R D; 2018 Mar; 18(1):1-5. PubMed ID: 29260458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium valproate and thrombocytopenia.
    Winfield DA; Benton P; Espir ML; Arthur LJ
    Br Med J; 1976 Oct; 2(6042):981. PubMed ID: 788857
    [No Abstract]   [Full Text] [Related]  

  • 35. IgM platelet autoantibody due to sodium valproate.
    Sandler RM; Emberson C; Roberts GE; Voak D; Darnborough J; Heeley AF
    Br Med J; 1978 Dec; 2(6153):1683-4. PubMed ID: 367512
    [No Abstract]   [Full Text] [Related]  

  • 36. [Thrombocyte values in adults during the treatment with DPA (Ergenyl)].
    Krause KH
    Med Welt; 1977 Jun; 28(24):1098-9. PubMed ID: 331015
    [No Abstract]   [Full Text] [Related]  

  • 37. Haematological disturbances during long-term valproate therapy.
    Brichard B; Vermylen C; Scheiff JM; Ninane J; Cornu G
    Eur J Pediatr; 1994 May; 153(5):378-80. PubMed ID: 8033931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder.
    Fawcett RG
    J Clin Psychiatry; 1997 Mar; 58(3):125. PubMed ID: 9108818
    [No Abstract]   [Full Text] [Related]  

  • 39. Predicting the occurrence of thrombocytopenia from free valproate levels: A prospective study.
    Nasreddine W; Atweh SF; Beydoun AA; Dirani M; Nawfal O; Beydoun A
    Seizure; 2022 Jan; 94():33-38. PubMed ID: 34864249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effect profile of enteric-coated divalproex sodium versus valproic acid.
    Levine J; Chengappa KN; Parepally H
    J Clin Psychiatry; 2000 Sep; 61(9):680-1. PubMed ID: 11030493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.